Marijke C. M. Gordijn
Research Subjects
Marijke C. M. Gordijn has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- A. Jan Willem Van Der Does
Department of Clinical Psychology, Leiden University, Leiden, The Netherlands
1 shared publication - Anne C. Berends
Seaborough Life Science, Amsterdam 1098 XG, The Netherlands
1 shared publication - Claudia J. P. Simons
Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Maastricht University, Vijverdalseweg 1, 6226 NB Maastricht, The Netherlands
1 shared publication - Eila G. Van Stipriaan
Vrije Universiteit Amsterdam
1 shared publication - Emma Visser
Human-Technology Interaction, Department of Industrial Engineering and Innovation Sciences, Eindhoven University of Technology, Eindhoven, The Netherlands
1 shared publication - Luc J. M. Schlangen
Human-Technology Interaction, School of Innovation Sciences, Eindhoven University of Technology, Eindhoven, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-27
BioClock—optimizing Bright Light Therapy for adults with depression: a study protocol for a multicenter randomized clinical trial on treatment strategies, response predictors, and chronobiological and neurobiological mechanisms
Background: Bright Light Therapy (BLT) is an effective treatment for various mood disorders, but challenges remain in optimizing its real-world administration, predicting individual responses, and understanding its mechanisms. Methods: This multicenter randomized controlled trial will enroll 231 patients with unipolar or bipolar depression, all currently experiencing a depressive episode. Participants will be randomized to one of three BLT interventions: (1) traditional home-based BLT, (2) BLT administered in the LightCafé—a novel setting promoting social interaction and lifestyle support, or (3) LightCafé BLT with personalized timing of both light and darkness by adding the use of blue light blocking glasses. The treatment duration will range from one to three weeks, based on preset definitions of participant’s response. The primary outcome is the change in depressive symptoms, assessed by a blinded rater. Secondary outcomes include subjective and objective sleep measures, circadian rhythm parameters from melatonin patterns and actigraphy, and functional outcomes. Change processes will be assessed using ecological momentary assessments of daily affect and energy levels, light exposure sensors, and via brain imaging. Discussion: This trial is the first to directly compare different BLT administration models, including a LightCafé setting. It aims to identify predictors of BLT response, investigate chronobiological and neurobiological mechanisms, and provide insights to optimize BLT for diverse patient populations. The results will inform clinical guidelines and enhance BLT's accessibility and effectiveness. Trial registration: Registered on July 14, 2023, at clinicaltrials.gov under number NCT05958940.
- 14 October 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-27
Open AccessBioClock—optimizing Bright Light Therapy for adults with depression: a study protocol for a multicenter randomized clinical trial on treatment strategies, response predictors, and chronobiological and neurobiological mechanisms
Background: Bright Light Therapy (BLT) is an effective treatment for various mood disorders, but challenges remain in optimizing its real-world administration, predicting individual responses, and understanding its mechanisms. Methods: This multicenter randomized controlled trial will enroll 231 patients with unipolar or bipolar depression, all currently experiencing a depressive episode. Participants will be randomized to one of three BLT interventions: (1) traditional home-based BLT, (2) BLT administered in the LightCafé—a novel setting promoting social interaction and lifestyle support, or (3) LightCafé BLT with personalized timing of both light and darkness by adding the use of blue light blocking glasses. The treatment duration will range from one to three weeks, based on preset definitions of participant’s response. The primary outcome is the change in depressive symptoms, assessed by a blinded rater. Secondary outcomes include subjective and objective sleep measures, circadian rhythm parameters from melatonin patterns and actigraphy, and functional outcomes. Change processes will be assessed using ecological momentary assessments of daily affect and energy levels, light exposure sensors, and via brain imaging. Discussion: This trial is the first to directly compare different BLT administration models, including a LightCafé setting. It aims to identify predictors of BLT response, investigate chronobiological and neurobiological mechanisms, and provide insights to optimize BLT for diverse patient populations. The results will inform clinical guidelines and enhance BLT's accessibility and effectiveness. Trial registration: Registered on July 14, 2023, at clinicaltrials.gov under number NCT05958940.
- Open Access
Effects of Near-Infrared Light on Well-Being and Health in Human Subjects with Mild Sleep-Related Complaints: A Double-Blind, Randomized, Placebo-Controlled Study
Modern urban human activities are largely restricted to the indoors, deprived of direct sunlight containing visible and near-infrared (NIR) wavelengths at high irradiance levels. Therapeutic exposure to doses of red and NIR, known as photobiomodulation (PBM), has been effective for a broad range of conditions. In a double-blind, randomized, placebo-controlled study, we aimed to assess the effects of a PBM home set-up on various aspects of well-being, health, sleep, and circadian rhythms in healthy human subjects with mild sleep complaints. The effects of three NIR light (850 nm) doses (1, 4, or 6.5 J·cm−2) were examined against the placebo. Exposure was presented five days per week between 9:30 am and 12:30 pm for four consecutive weeks. The study was conducted in both summer and winter to include seasonal variation. The results showed PBM treatment only at 6.5 J·cm−2 to have consistent positive benefits on well-being and health, specifically improving mood, reducing drowsiness, reducing IFN-γ, and resting heart rate. This was only observed in winter. No significant effects on sleep or circadian rhythms were noted. This study provides further evidence that adequate exposure to NIR, especially during low sunlight conditions, such as in the winter, can be beneficial for human health and wellness.
Open AccessEffects of Near-Infrared Light on Well-Being and Health in Human Subjects with Mild Sleep-Related Complaints: A Double-Blind, Randomized, Placebo-Controlled Study
Modern urban human activities are largely restricted to the indoors, deprived of direct sunlight containing visible and near-infrared (NIR) wavelengths at high irradiance levels. Therapeutic exposure to doses of red and NIR, known as photobiomodulation (PBM), has been effective for a broad range of conditions. In a double-blind, randomized, placebo-controlled study, we aimed to assess the effects of a PBM home set-up on various aspects of well-being, health, sleep, and circadian rhythms in healthy human subjects with mild sleep complaints. The effects of three NIR light (850 nm) doses (1, 4, or 6.5 J·cm−2) were examined against the placebo. Exposure was presented five days per week between 9:30 am and 12:30 pm for four consecutive weeks. The study was conducted in both summer and winter to include seasonal variation. The results showed PBM treatment only at 6.5 J·cm−2 to have consistent positive benefits on well-being and health, specifically improving mood, reducing drowsiness, reducing IFN-γ, and resting heart rate. This was only observed in winter. No significant effects on sleep or circadian rhythms were noted. This study provides further evidence that adequate exposure to NIR, especially during low sunlight conditions, such as in the winter, can be beneficial for human health and wellness.
- Open Access
- 2 September 2022
- Published by MDPI AG in Clocks & Sleep
- Vol. 4 (3) , 412-457
33rd Annual Meeting of the Society for Light Treatment and Biological Rhythms (SLTBR), 23–25 June 2022, Manchester, UK
The 33rd annual meeting of the Society for Light Treatment and Biological Rhythms was held in Manchester in June 2022
- 2 September 2022
- Published by MDPI AG in Clocks & Sleep
- Vol. 4 (3) , 412-457
Open Access33rd Annual Meeting of the Society for Light Treatment and Biological Rhythms (SLTBR), 23–25 June 2022, Manchester, UK
The 33rd annual meeting of the Society for Light Treatment and Biological Rhythms was held in Manchester in June 2022
- 1 September 2018
- Published by Elsevier in Applied Ergonomics
- Vol. 71, 87-94
Investigating daily fatigue scores during two-week offshore day shifts
- 1 September 2018
- Published by Elsevier in Applied Ergonomics
- Vol. 71, 87-94
Investigating daily fatigue scores during two-week offshore day shifts